Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/28987
Başlık: Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
Yazarlar: Heathcote, E. Jenny
Marcellin, Patrick
Buti, Maria
Gane, Edward
De Man, Robert A.
Krastev, Zahary
Germanidis, George
Lee, Samuel S.
Flisiak, Robert
Kaita, Kelly
Manns, Michael
Kotzev, Iskren
Tchernev, Konstantin
Buggisch, Peter
Weilert, Frank
Kurdas, Oya Ovunc
Shiffman, Mitchell L.
Trinh, Huy
Snow-Lampart, Andrea
Borroto, Katyna Esoda
Mondou, Elsa
Anderson, Jane
Sorbel, Jeff
Rousseau, Franck
Uludağ Üniversitesi/Tıp Fakültesi/ İç Hastalıkları Anabilim Dalı.
Gürel, Selim
7003706434
Anahtar kelimeler: Gastroenterology & hepatology
Liver disease
Virology
Drug resistance
Viral replication
Nucleotide
Hbeag-positive patients
Term-follow-up
Serum hbsag
Peginterferon alpha-2a
Adefovir dipivoxil
Sustained response
Negative patients
Natural-history
Virus-infection
Dna level
Yayın Tarihi: Oca-2011
Yayıncı: Elsevier
Atıf: Heathcote, E. J. vd. (2011). "Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B". Gastroenterology, 140(1), 132-143.
Özet: BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir dipivoxil in treatment of chronic hepatitis B through 48 weeks. We evaluated long-term efficacy and safety of TDF monotherapy in patients with chronic hepatitis B who were positive or negative for hepatitis B e antigen (HBeAg+ or HBeAg-). METHODS: After 48 weeks of double-blind comparison of TDF to adefovir dipivoxil, patients who underwent liver biopsy were eligible to continue the study on open-label TDF for 7 additional years; data presented were collected up to 3 years (week 144) from 85% of participants. Primary efficacy end points at week 144 included levels of HBV DNA and alanine aminotransferase, development of resistance mutations, and presence of HBeAg or hepatitis B surface antigen (HBsAg). RESULTS: At week 144, 87% of HBeAg- and 72% of HBeAg+ patients treated with TDF had levels of HBV DNA <400 copies/mL. Among patients who had previously received adefovir dipivoxil and then received TDF, 88% of the HBeAg- and 71% of the HBeAg+ patients had levels of HBV DNA <400 copies/mL; overall, 81% and 74%, respectively, maintained normalized levels of alanine aminotransferase and 34% had lost HBeAg. Amino acid substitutions in HBV DNA polymerase that are associated with resistance to tenofovir were not detected in any patient. Cumulatively, 8% of HBeAg+ patients lost HBsAg. TDF maintained a favorable safety profile for up to 3 years. CONCLUSIONS: TDF was safe and effective in the long-term management of HBeAg+ and HBeAg- patients with chronic hepatitis B.
URI: https://doi.org/10.1053/j.gastro.2010.10.011
https://pubmed.ncbi.nlm.nih.gov/20955704/
http://hdl.handle.net/11452/28987
ISSN: 0016-5085
1528-0012
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.